Long-term follow-up for a prior gene-cell treatment
Part of Infections clinical trials.
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously received AGT103-T through the sponsor’s earlier AGT-HC168 study
- You agree to participate by signing and dating a consent form for long-term follow-up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks your health over time after you previously received gene-modified cell therapy in a Sorrento-sponsored trial. It helps researchers understand long-term safety and outcomes and may lead to better care for future patients.
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
This study is a follow-up check for people who were previously enrolled in certain NCI gene therapy treatment studies. It helps the research team monitor long-term effects and outcomes after treatment.
This study follows people for many years after they receive gene therapy (a treatment that uses lab-made genetic material). It mainly checks long-term safety and health outcomes and may help doctors understand how gene therapy works over time.
This study checks long-term health after receiving a gene-modified cell therapy through a St. Jude study. It helps doctors understand the treatment’s lasting effects and safety over time.
This study is a long-term safety check for people who have already received a gene modified T cell treatment in a previous study sponsored by 2seventy bio or Regeneron Pharmaceuticals. The goal is to monitor your health for years after that treatment to see how well it works and if any side effects appear over time.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.